Clinical observations have shown that migraine is a progressive disorder, both within an
acute attack, and within the disease itself. Rates of diagnosis for migraine have increased in …

Background Comparative evaluations of preventive migraine treatments can help inform
clinical decision making for managing migraine in clinical practice. Methods An anchored …

Background Migraine is common in children and adolescents and can be disabling. Being
able to predict which patients will respond to triptans based on their clinical phenotype …

Importance Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist under
investigation for acute treatment of migraine. Objective To evaluate the efficacy and …

The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine
drugs. Soon, seven different triptans will be clinically available at 13 different oral doses …

Objective To assess the influence of switching acute treatment on headache‐related
disability in a population sample of individuals with migraine using acute triptan therapy …

Over the last 10 years, triptans (serotonin 5-HT1B/1D receptor agonists) have proved to be
efficacious in treating migraine pain. However, recent evidence suggests that patients are …

Oral triptan therapy. Only oral formulations currently available in the UK plus eletriptan
(licensed, but not yet launched in the UK) were considered for inclusion. Studies relating to …

Background No acute treatments targeting calcitonin gene-related peptide (CGRP) have
been approved for use in China or South Korea. We aimed to compare the efficacy and …

Migraine is three times as common in females as in males, and attacks may be more severe
and difficult to treat in women. However, no study specifically addressed possible gender …